Early marker of proteinuria in patients treated with an anti-VEGF treatment

摘要

This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.

主权项

1. A method for using an anti-VEGF therapy, without inducing proteinuria, to treat cancer in a human having cancer, wherein said method comprises:
(a) administering an initial dose of said anti-VEGF therapy to said human to treat said cancer, (b) obtaining a urine sample from said human receiving said anti-VEGF therapy, (c) contacting said urine sample with an antibody that binds to podocytes or polypeptides expressed by podocytes to form an antigen-antibody complex, if podoycytes or polypeptides expressed by podocytes are present in said sample, (d) detecting, by flow cytometry, the presence of said antigen-antibody complex, thereby identifying said human as being at risk of developing proteinuria, if said complex is detected and (e) administering a subsequent dose of said anti-VEGF therapy to said human who does not have proteinuria, but in whom the antigen-antibody complex has been detected, wherein said subsequent dose is at least 30 percent lower than said initial dose.